Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
1004 Venture Partners is a venture capital firm established to invest in early-stage startups within the healthcare and longevity sectors. Founded by Soyoung Park, the firm derives its name from the Korean and Japanese pronunciation of 'angel,' reflecting its mission to support entrepreneurs in making impactful advancements in healthy aging. The firm operates out of the United States and has a growing portfolio of life science investments.
Currently, 1004 Venture Partners has made over 20 investments in emerging life science companies, with a notable focus on technologies that promote healthy aging. The firm has achieved three successful exits, including a significant acquisition of a sickle cell disease company by Pfizer for $5.6 billion. This milestone underscores the firm's commitment to backing transformative technologies that address critical health challenges.
1004 Venture Partners emphasizes mentorship and aims to connect founders with a network of industry professionals, investors, and key opinion leaders. This approach not only supports business growth but also enhances the potential for successful outcomes in the healthcare and longevity sectors.
1004 Venture Partners invests primarily in early-stage startups that are developing transformative technologies in the healthcare and longevity sectors. The firm targets companies at the Pre-Seed, Seed, and Seed+ (Extension) stages, focusing on innovative solutions that address age-related diseases and promote healthy aging. Their investment strategy encompasses a range of sectors, including age tech, health tech, healthcare infrastructure, biotech, and neuro-therapeutics.
The firm is particularly interested in startups that demonstrate translational clarity and have well-defined de-risking roadmaps. 1004 Venture Partners is comfortable leading investment rounds when conviction is strong and often syndicates with quality co-investors to enhance funding opportunities. Their thesis revolves around the concept of 'healthy aging,' which includes prevention, diagnostics, and therapeutics aimed at age-related diseases.
In their own words, the firm believes that if they can keep the aging population healthy, individuals can remain productive and independent. This perspective drives their investment decisions and the support they provide to portfolio companies.
1004 Venture Partners has built a diverse portfolio of over 20 life science investments, with a focus on companies that are pioneering advancements in healthcare and longevity. Notable companies in their portfolio include:
These investments reflect 1004 Venture Partners' commitment to supporting innovative solutions that address critical health issues and promote longevity.
Soyoung Park - Founder & General Partner. Soyoung Park established 1004 Venture Partners with a global perspective on healthy aging investments. She emphasizes the importance of supporting entrepreneurs in the healthcare sector.
David Crean - Partner. David Crean leads Cardiff Advisory LLC and focuses on backing pre-seed through Series A companies in the longevity economy. He has been featured in various podcasts discussing biotech investment strategies and prioritizes platforms with translational clarity.
To pitch 1004 Venture Partners, founders should submit their proposals through the firm's website at 1004venturepartners.com. It is essential to include a comprehensive pitch deck that outlines the startup's vision, technology, market opportunity, and team qualifications.
While specific response times are not disclosed, founders can expect a thorough review process. Warm introductions are preferred, as they can facilitate a more favorable reception of the pitch.
In recent months, 1004 Venture Partners has made over 20 investments in emerging life science companies, showcasing their active role in the sector. One of their notable recent investments includes Sinaptica, a neuromodulation startup that has garnered attention for its innovative approach to Alzheimer's treatment.
The firm has also achieved three successful exits, including a significant acquisition of a sickle cell disease company by Pfizer for $5.6 billion. This exit highlights the firm's ability to identify and support high-potential startups in the healthcare space.
What are the investment criteria for 1004 Venture Partners?
1004 Venture Partners focuses on early-stage startups in the healthcare and longevity sectors, particularly those developing transformative technologies. They prioritize companies with clear translational pathways and de-risking strategies.
How can I pitch to 1004 Venture Partners?
Founders can pitch their startups through the firm's website at 1004venturepartners.com. It is advisable to include a detailed overview of the technology, market potential, and team background in the pitch deck.
What makes 1004 Venture Partners different from other VCs?
The firm emphasizes mentorship and connections to industry professionals, which enhances the support provided to portfolio companies. Their focus on healthy aging and longevity sets them apart in the venture capital landscape.
What is the geographic scope of 1004 Venture Partners?
1004 Venture Partners is based in the United States but is open to investing in promising startups globally, particularly those that align with their focus on healthcare and longevity.
What is the typical check size for investments?
While specific check sizes are not disclosed, 1004 Venture Partners invests in early-stage rounds, typically ranging from Pre-Seed to Series A funding.
What kind of post-investment involvement can founders expect?
Founders can expect active mentorship and support from 1004 Venture Partners, including access to a network of industry professionals and potential follow-on investment opportunities.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.